Skip to content
Company Analysis

Petros Pharmaceuticals, Inc. PTPI

A comprehensive view of key metrics, scores, and financial health for Petros Pharmaceuticals, Inc.

Overview of Petros Pharmaceuticals, Inc.

PTPI PNK
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Micro Cap
Petros Pharmaceuticals, Inc. (PTPI), is a Micro Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $0.00, about 0.0% overvalued vs fair value, -78.9% 1Y return, ranked 1128/1145 in sector.
Metrics P/E 0.2× ROE -83.3%
USD 0.00
100.00%
(Delayed)
• Vol 90d: 285.3%
52-Week Range
Market Cap
$148,304
Enterprise Value
$-1.53M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 76%
Confidence: 83%
Updated: Oct 31
Top Beats
No strong beats yet

Quick Facts

Website https://petrospharma.com
HQ New York, NY
Employees 18
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Insufficient data
Show more details
  • Revenue data missing or non-positive

Engine Room Money Flow™

Micro Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$0
Gross Profit
$0
R&D Expense
$2.6M
8.5%%
Operating Income (EBIT)
-$4.6M
-0.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$341.6K

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
1/3
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Petros Pharmaceuticals, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
25
/100
Weak
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key risks

  • ROIC Below WACC or Peers ROIC at 9.8th percentile suggests inefficient capital deployment.
  • Below-Peer Operating Efficiency Operating margin at 15.0th percentile indicates below-peer efficiency.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
28
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 72% Coverage
Trade-Off Triangle Visualization A ternary plot showing PTPI's balance between Growth (36.1%), Profitability (23.0%), and Safety (40.9%). Growth 36% Safety 41% Profitability 23%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

35th percentile vs peers
35
Key Signals
EPS Growth YoY 1.00 80p Rev Growth YoY -1.00 5p
Strengths
  • EPS Growth YoY in top 20% of peers (1.00, 80th percentile)
  • Debt/FCF Ratio in top 20% of peers (-2.78, 91th percentile)
Risks
  • Rev Growth YoY in bottom 20% of peers (-1.00)

Profitability

22th percentile vs peers
23
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

40th percentile vs peers
40
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Petros Pharmaceuticals, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000